ACRV (Acrivon Therapeutics) Construction In Progress: $0.92 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRV Acrivon Therapeutics Inc ACRV
35 GF Score
Price $1.72
! 3 Warning Signs
View Full Analysis

What is Acrivon Therapeutics Construction In Progress?

Acrivon Therapeutics ACRV -0.29% 35 Construction In Progress is $0.92 Mil as of Mar. 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Acrivon Therapeutics's quarterly construction in progress declined from Sep. 2025 ($1.24 Mil) to Dec. 2025 ($0.92 Mil) but then stayed the same from Dec. 2025 ($0.92 Mil) to Mar. 2026 ($0.92 Mil).

Acrivon Therapeutics's annual construction in progress declined from Dec. 2023 ($1.31 Mil) to Dec. 2024 ($0.06 Mil) but then increased from Dec. 2024 ($0.06 Mil) to Dec. 2025 ($0.92 Mil).

Acrivon Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Acrivon Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrivon Therapeutics Construction In Progress Chart

Acrivon Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 0.00 0.00 1.31 0.06 0.92

Acrivon Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 1.10 1.24 0.92 0.92
ACRV
35GF Score
Acrivon Therapeutics Inc ACRV
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acrivon Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.92 Mil mean?
Acrivon Therapeutics (ACRV) has a Construction In Progress of $0.92 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Acrivon Therapeutics and its competitors.
Is Acrivon Therapeutics' Construction In Progress too high?
Acrivon Therapeutics' current Construction In Progress is $0.92 Mil. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Construction In Progress compare to SPRO and BSEM?
Acrivon Therapeutics' Construction In Progress of $0.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Acrivon Therapeutics and its competitors. Acrivon Therapeutics's current Construction In Progress is $0.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Construction In Progress of $0.92 Mil. The current Construction In Progress is $0.92 Mil. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Construction In Progress is $0.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acrivon Therapeutics Business Description

Address 480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score

Get the complete analysis for ACRV

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price